Figure 7
From: Docosahexaenoic acid (DHA): a modulator of microglia activity and dendritic spine morphology
Summarizing schematic: DHA treatment prevents microglial activation, LB aggregation and dendritic spine loss. LPS causes microglial activation, nitric oxide release, p38 phosphorylation and increases in LB size, while it decreases dendritic spine densities in neurons. However, DHA treatment can prevent LPS-induced effects. DHA decreases nitric oxide release, p38 phosphorylation and LB size, and it restores dendritic spine densities.